Yifan Pharmaceutical Co., Ltd. (002019.SZ)
CNY 11.34
(-2.99%)
CNY 11.34
(-2.99%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -483.52 Million CNY | -53.92% |
| 2022 | 471.01 Million CNY | 12.97% |
| 2021 | 492.55 Million CNY | -59.08% |
| 2020 | 1.34 Billion CNY | -3.13% |
| 2019 | 1.3 Billion CNY | 21.98% |
| 2018 | 1.06 Billion CNY | -35.11% |
| 2017 | 1.7 Billion CNY | 59.89% |
| 2016 | 1.03 Billion CNY | 91.31% |
| 2015 | 541.86 Million CNY | 73.19% |
| 2014 | 327.8 Million CNY | 184.28% |
| 2013 | 117.61 Million CNY | -14.35% |
| 2012 | 96.62 Million CNY | 1750.26% |
| 2011 | -159.38 Million CNY | -51.02% |
| 2010 | -135.81 Million CNY | -81.46% |
| 2009 | 78.55 Million CNY | -32.88% |
| 2008 | 106.58 Million CNY | -69.7% |
| 2007 | 397.93 Million CNY | 723.98% |
| 2006 | 54.97 Million CNY | -24.26% |
| 2005 | 64.39 Million CNY | -0.1% |
| 2004 | 64.46 Million CNY | 29.53% |
| 2003 | 49.76 Million CNY | 57.29% |
| 2002 | 31.64 Million CNY | 17.31% |
| 2001 | 26.97 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 117.07 Million CNY | -53.01% |
| 2024 Q1 | 193.84 Million CNY | 120.66% |
| 2024 Q2 | 193.17 Million CNY | 28.54% |
| 2023 FY | - CNY | -53.92% |
| 2023 Q2 | 131.09 Million CNY | 94.85% |
| 2023 Q1 | 67.27 Million CNY | -37.17% |
| 2023 Q3 | 59.25 Million CNY | -54.8% |
| 2023 Q4 | -938.35 Million CNY | -1683.59% |
| 2022 Q1 | 161.49 Million CNY | 1209.67% |
| 2022 FY | - CNY | 12.97% |
| 2022 Q2 | 62.48 Million CNY | -61.31% |
| 2022 Q4 | 107.07 Million CNY | 56.73% |
| 2022 Q3 | 68.31 Million CNY | 9.34% |
| 2021 Q4 | -14.55 Million CNY | -118.05% |
| 2021 Q2 | 112.72 Million CNY | -33.6% |
| 2021 Q3 | 80.61 Million CNY | -28.49% |
| 2021 Q1 | 169.77 Million CNY | 269.41% |
| 2021 FY | - CNY | -59.08% |
| 2020 FY | - CNY | -3.13% |
| 2020 Q4 | 45.95 Million CNY | -80.93% |
| 2020 Q3 | 241.03 Million CNY | -49.95% |
| 2020 Q2 | 481.6 Million CNY | 15.48% |
| 2020 Q1 | 417.04 Million CNY | 39.97% |
| 2019 Q1 | 212.46 Million CNY | 46.46% |
| 2019 Q2 | 441.3 Million CNY | 107.71% |
| 2019 Q3 | 302.68 Million CNY | -31.41% |
| 2019 Q4 | 297.95 Million CNY | -1.56% |
| 2019 FY | - CNY | 21.98% |
| 2018 Q4 | 145.07 Million CNY | -33.73% |
| 2018 Q3 | 218.89 Million CNY | 1.1% |
| 2018 FY | - CNY | -35.11% |
| 2018 Q1 | 452.52 Million CNY | -8.67% |
| 2018 Q2 | 216.52 Million CNY | -52.15% |
| 2017 Q4 | 495.5 Million CNY | -8.92% |
| 2017 Q3 | 544.02 Million CNY | 40.47% |
| 2017 Q2 | 387.27 Million CNY | 40.78% |
| 2017 Q1 | 275.09 Million CNY | 18.8% |
| 2017 FY | - CNY | 59.89% |
| 2016 Q3 | 290.5 Million CNY | -7.87% |
| 2016 Q2 | 315.33 Million CNY | 71.88% |
| 2016 Q1 | 183.46 Million CNY | 6.84% |
| 2016 Q4 | 231.56 Million CNY | -20.29% |
| 2016 FY | - CNY | 91.31% |
| 2015 FY | - CNY | 73.19% |
| 2015 Q3 | 95.92 Million CNY | -12.08% |
| 2015 Q4 | 171.72 Million CNY | 79.03% |
| 2015 Q2 | 109.09 Million CNY | -10.96% |
| 2015 Q1 | 122.52 Million CNY | -9.16% |
| 2014 Q1 | 48.75 Million CNY | 274.98% |
| 2014 Q3 | 62.11 Million CNY | -12.37% |
| 2014 Q4 | 134.87 Million CNY | 117.13% |
| 2014 FY | - CNY | 184.28% |
| 2014 Q2 | 70.88 Million CNY | 45.41% |
| 2013 FY | - CNY | -14.35% |
| 2013 Q2 | 9.83 Million CNY | -47.04% |
| 2013 Q3 | 17.61 Million CNY | 79.03% |
| 2013 Q4 | 13 Million CNY | -26.18% |
| 2013 Q1 | 18.57 Million CNY | -70.24% |
| 2012 Q2 | 36.83 Million CNY | 198.51% |
| 2012 Q1 | 12.34 Million CNY | 130.91% |
| 2012 Q4 | 62.41 Million CNY | 1045.45% |
| 2012 FY | - CNY | 1750.26% |
| 2012 Q3 | 5.44 Million CNY | -85.21% |
| 2011 Q4 | -39.91 Million CNY | -534.73% |
| 2011 FY | - CNY | -51.02% |
| 2011 Q1 | -3.98 Million CNY | 89.21% |
| 2011 Q2 | 2.35 Million CNY | 158.98% |
| 2011 Q3 | 9.18 Million CNY | 290.49% |
| 2010 Q2 | 12.38 Million CNY | 124.46% |
| 2010 Q4 | -36.93 Million CNY | -478.38% |
| 2010 FY | - CNY | -81.46% |
| 2010 Q1 | 5.51 Million CNY | -31.29% |
| 2010 Q3 | -6.38 Million CNY | -151.54% |
| 2009 Q2 | 8.68 Million CNY | -27.71% |
| 2009 Q1 | 12.01 Million CNY | 304.82% |
| 2009 FY | - CNY | -32.88% |
| 2009 Q4 | 8.03 Million CNY | -52.45% |
| 2009 Q3 | 16.89 Million CNY | 94.45% |
| 2008 Q4 | -5.86 Million CNY | -328.66% |
| 2008 Q2 | 31.22 Million CNY | -48.84% |
| 2008 Q3 | 2.56 Million CNY | -91.78% |
| 2008 Q1 | 61.03 Million CNY | -46.68% |
| 2008 FY | - CNY | -69.7% |
| 2007 Q2 | 108.98 Million CNY | 203.71% |
| 2007 FY | - CNY | 723.98% |
| 2007 Q4 | 114.46 Million CNY | 2.97% |
| 2007 Q3 | 111.16 Million CNY | 2.01% |
| 2007 Q1 | 35.88 Million CNY | 1277.57% |
| 2006 Q3 | 14.68 Million CNY | 23.79% |
| 2006 Q1 | 21.13 Million CNY | 1349.04% |
| 2006 FY | - CNY | -24.26% |
| 2006 Q2 | 11.86 Million CNY | -43.87% |
| 2006 Q4 | -3.04 Million CNY | -120.74% |
| 2005 Q4 | 1.45 Million CNY | -95.73% |
| 2005 FY | - CNY | -0.1% |
| 2005 Q2 | 20.05 Million CNY | 13.76% |
| 2005 Q1 | 17.62 Million CNY | 37.33% |
| 2005 Q3 | 34.13 Million CNY | 70.2% |
| 2004 Q4 | 12.83 Million CNY | 20.77% |
| 2004 FY | - CNY | 29.53% |
| 2004 Q1 | 14.67 Million CNY | 41.68% |
| 2004 Q2 | 17.03 Million CNY | 16.07% |
| 2004 Q3 | 10.62 Million CNY | -37.59% |
| 2003 Q3 | 5.11 Million CNY | 0.0% |
| 2003 Q4 | 10.35 Million CNY | 102.52% |
| 2003 FY | - CNY | 57.29% |
| 2002 FY | - CNY | 17.31% |
| 2001 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 1.14 Billion CNY | 142.354% |
| Zhejiang Zhenyuan Share Co., Ltd. | 220.46 Million CNY | 319.324% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | -83.34 Million CNY | -480.165% |
| Hubei Guangji Pharmaceutical Co., Ltd. | -2.67 Million CNY | -17997.839% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 66.15 Million CNY | 830.945% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 4.85 Billion CNY | 109.954% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | 116.49 Million CNY | 515.064% |
| Boai NKY Medical Holdings Ltd. | 665.28 Million CNY | 172.679% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 391.09 Million CNY | 223.634% |